NCT03001609View on ClinicalTrials.gov

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

September 30, 2017

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

AC0010

Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]

Trial Locations (1)

210029

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

INDUSTRY

NCT03001609 - Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC | Biotech Hunter | Biotech Hunter